[Erratum in "Point-of-Care Blood Glucose Testing: Post-Market Performance Assessment of the Accu-Chek Inform II Hospital-Use Glucose Meter" (DOI: 10.26442/00403660.2023.12.202522)].

In the article "Point-of-care blood glucose testing: post-market performance assessment of the Accu-Chek Inform II hospital-use glucose meter," published in the Terapevticheskii Arkhiv journal, Vol. 95, No.12, 2023 (DOI: 10.26442/00403660.2023.12.202522), errors were made: the term "measurements at the place of treatment" was changed, as well as the section "Conflict of interest." At the request of the authors' team, errors in the conflict of interest and the wording of the term have been corrected, and the section "Information about the authors" has been updated. The publisher replaced the original version of the published article with the corrected one; the information on the website was also corrected. Correct text of the section "Conflict of interest": Conflict of interest. All authors are not employees or consultants of Roche Diagnostics and have not received any compensation from Roche Diagnostics. Correct wording of the term in Russian: "измерения по месту лечения". Changes were made to the title of the article in Russian: "Измерения глюкозы по месту лечения: пострегистрационное испытание госпитального глюкометра Акку-Чек Информ II", the text of the abstract, keywords, citation, in the text of the article, and abbreviations. Information of the place of work has been updated: Center for Laboratory Diagnostics of the Russian Children Clinical Hospital, a Branch of the Pirogov Russian National Research Medical University. The publisher apologizes to readers and authors for the errors and is confident that the correction of errors will ensure the correct perception and interpretation of the results of the study described in the text.

[Point-of-Care Blood Glucose Testing: Post-Market Performance Assessment of the Accu-Chek Inform II Hospital-Use Glucose Meter].

BACKGROUND: A point-of-care glucose testing (POCT) is an essential component of care in patients with hyperglycemia and hypoglycemia in inpatient and outpatient settings. In Russian medical facilities (MFs), conventional glucose meters designed for self-monitoring by patients with diabetes are commonly used for POCT. These home-use meters have two serious disadvantages: the first is large measurement bias and the second - they can't be integrated into laboratory information systems, so measurement data have to be recorded into patient charts manually. Both factors may lead to medical errors. It is reasonable to use in the MFs specialized POCT glucose meters, as they are superior to conventional ones in accuracy and may be easily connected to laboratory information systems. With this in mind, physicians at the Russian Children's Clinical Hospital decided to substitute conventional meters with the Accu-Chek Inform II POCT meter, however, after preliminary performance assessment of the model. AIM: To test the Accu-Chek Inform II performance characteristics: accuracy, linearity, repeatability, and mean absolute relative difference (MARD). MATERIALS AND METHODS: Performance of the Accu-Chek Inform II was tested by comparing the results of parallel CGL measurements with the meter and reference laboratory analyzer in capillary blood samples. Overall, 99 parallel CGL measurements were made in 45 samples. Accuracy was evaluated according to the ISO 15197-2013 and POCT12-A3 criteria. RESULTS: The Accu-Chek Inform II meter met the requirements of ISO 15197-2013 and POCT12-A3 and demonstrated high linearity (correlation coefficient, r=1,0), good repeatability (mean coefficient of variation, CV=1,38%) and acceptable MARD (4,9%). CONCLUSION: The Accu-Chek Inform II POCT glucose meter may be efficiently and safely used in inpatient and outpatient MFs and particularly in pediatric clinics.

[Differential diagnosis of diabetes mellitus in adults: assessment of immunogenetic markers of insulin dependence]. / Problemy differentsial'noi diagnostiki sakharnogo diabeta u vzroslykh: otsenka immunogeneticheskikh markerov insulinozavisimosti.

To assess immunogenetic markers of insulin dependence (IMID), 117 patients with diabetes mellitus of the adults (DMA) were examined. Of them, 97 patients (77 females and 20 males, 41 and 10 obese, respectively) were insulin dependent and 20 (8 males and 12 females) had classic diabetes mellitus (DM) type 2. All the analysed immunogenetic markers (genotype SS/SS, alleles 04*, 0301 in HLA-DQ*A2, haplotype A1*0301-B1*0302) were associated most often with insulin-dependent DMA. The following conclusions were made: both DMA variants can be definitely differentiated only by clinico-anamnestic screening; there were no differences in distribution of the alleles 0301 in DQ*A1 and 0302 in DQ*B1 in different variants of DMA; alleles 04* and 0301 DQ*A1 significantly more frequently occur in DM type 1 than DM type 2; 0301 allele was more frequent in patients with insulin-dependent DM type 2 vs DM type 2; an expectant genetic marker of insulin-dependence (haplotype 0301/0302) occurs significantly more frequently in insulin-dependent DMA than in healthy subjects and DM type 2.

[Comparative analysis of tests on in vitro and in vivo quantitative assessment of the immunogenicity of tick-borne encephalitis vaccine]. / Sravnitel'nyi analiz testov in vitro i in vivo kolichestvennoi otsenki immunogennosti vaktsiny kleshchevogo éntsefalita.

Many-year routine use of EIA as an in vitro test demonstrated it as a highly reproducible and technological test for assessing the efficacy of vaccine against tick-borne encephalitis and its semiproducts at the intermediate stages of vaccine production. The reproducibility of mouse protection test is notably inferior to that of EIA.